Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Cyxone AB (publ)    CYXO   SE0007815428

CYXONE AB (PUBL)

(CYXO)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Cyxone : The largest shareholder of Aptahem suggests Dr Bert Junno as the new Chairman of the Board

share with twitter share with LinkedIn share with facebook
09/17/2020 | 02:31am EDT

Aptahem AB (publ), announce today that the company's largest shareholder, Ivar Nordqvist, suggests Dr Bert Junno to be elected new Chairman of the Board at the coming Extraordinary General Meeting on 25 September 2020. This after the former Chairman of the Board, Dr Kjell G Stenberg, requested his own resignation.

Dr Junno, born in 1966, is currently the Chairman of the Board of Cyxone AB (publ) and CombiGene AB (publ) and board member of Accequa AB and Accequa GmbH. He has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. He has also co-founded several life science companies, for example WntResearch AB (publ), Galecto Biotech AB, Gabather AB (publ), Aptahem AB (publ) and Cyxone AB (publ). Dr Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University. Dr Junno does not hold any shares in Aptahem.

"Bert Junno is probably well known for those close to Aptahem, for example as a previous member of the board. His long experience from several board assignments and his solid knowledge in IP and partnering in research based small companies makes him well suited to lead the Board of Directors in the next phase of Aptahem's development" comments Ivar Nordqvist.

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

This information was provided through the agency of the contact person above, for publication on 17 September 2020.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

https://news.cision.com/aptahem/r/the-largest-shareholder-of-aptahem-suggests-dr-bert-junno-as-the-new-chairman-of-the-board,c3195459

https://mb.cision.com/Main/12121/3195459/1307243.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
All news about CYXONE AB (PUBL)
05:31pCYXONE : revises the development plan for Rabeximod
AQ
09/17CYXONE : raises SEK 1 million in a second directed share issue under the agreeme..
AQ
09/17CYXONE : The largest shareholder of Aptahem suggests Dr Bert Junno as the new Ch..
AQ
09/15BIOSTOCK : Tara Heitner is ready to take Cyxone to the next level
AQ
09/14CYXONE : plans to initiate a phase 2 clinical trial with Rabeximod in Covid-19 p..
AQ
09/08CYXONE : First Berlin Equity Research publishes independent analysis of Cyxone
AQ
09/04BIOSTOCK : Cyxone is looking forward to an eventful autumn
AQ
08/28CYXONE : Interim Report 1 January to 30 June 2020
AQ
More news
Financials
Sales 2020 0,03 M 0,00 M 0,00 M
Net income 2020 - - -
Net cash 2020 20,8 M 2,28 M 2,28 M
P/E ratio 2020 -
Yield 2020 -
Capitalization 321 M 35,1 M 35,2 M
EV / Sales 2020 9 999x
EV / Sales 2021 10 139x
Nbr of Employees 3
Free-Float 100%
Chart CYXONE AB (PUBL)
Duration : Period :
Cyxone AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 12,70 SEK
Last Close Price 6,48 SEK
Spread / Highest target 96,0%
Spread / Average Target 96,0%
Spread / Lowest Target 96,0%
Managers
NameTitle
Tara Heitner Chief Executive Officer & Director
Bert Roland Kari Junno Chairman
Malin Berthold Chief Operating Officer
Ola Skanung Chief Financial Officer
Saad Urrehman Gilani Director
Sector and Competitors
1st jan.Capitalization (M$)
CYXONE AB (PUBL)54.65%37
MERCK KGAA18.37%63 337
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD110.25%20 935
KYOWA KIRIN CO., LTD.12.24%14 664
BETTA PHARMACEUTICALS CO., LTD.74.79%6 854
YUHAN CORPORATION30.87%3 477